Sunshine Biopharma, Inc.

NasdaqCM:SBFM Stock Report

Market Cap: US$5.6m

Sunshine Biopharma Future Growth

Future criteria checks 5/6

Sunshine Biopharma is forecast to grow earnings and revenue by 208.2% and 109.9% per annum respectively while EPS is expected to grow by 161.9% per annum.

Key information

208.2%

Earnings growth rate

161.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate109.9%
Future return on equityn/a
Analyst coverage

Low

Last updated05 Dec 2024

Recent future growth updates

No updates

Recent updates

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues

Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Jan 29
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues

Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sep 12
Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch

Sunshine Biopharma acquires Nora Pharma for C$30M

Oct 20

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Aug 08
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Sunshine Biopharma reports 1H results

Aug 04

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Apr 17

Earnings and Revenue Growth Forecasts

NasdaqCM:SBFM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202510012N/AN/A1
12/31/202428-3N/AN/A1
9/30/202433-4-14-12N/A
6/30/202430-4-12-11N/A
3/31/202427-4-11-10N/A
12/31/202324-5-10-9N/A
9/30/202320-27-9-8N/A
6/30/202315-28-10-9N/A
3/31/20239-27-6-6N/A
12/31/20224-27-6-5N/A
9/30/20220-3-3-3N/A
6/30/20220-5-3-3N/A
3/31/20220-7-3-3N/A
12/31/20210-12-2-2N/A
9/30/20210-14-2-2N/A
6/30/20210-11-1-1N/A
3/31/20210-9-1-1N/A
12/31/20200-3-1-1N/A
9/30/20200-200N/A
6/30/20200-200N/A
3/31/20200-100N/A
12/31/20190-100N/A
9/30/20190-100N/A
6/30/20190-2-1-1N/A
3/31/20190-2-1-1N/A
12/31/2018N/A-2-1-1N/A
9/30/2018N/A-2-1-1N/A
6/30/2018N/A-1N/A-1N/A
3/31/20180-1N/A-1N/A
12/31/2017N/A-1N/A-1N/A
9/30/2017N/A-2N/A0N/A
6/30/2017N/A-3N/A0N/A
3/31/2017N/A-3N/A0N/A
12/31/2016N/A-3N/A0N/A
9/30/2016N/A-3N/A-1N/A
6/30/2016N/A-2N/A-1N/A
3/31/20160-2N/A-1N/A
12/31/20150-2N/A-1N/A
9/30/20150-1N/A-1N/A
6/30/20150-1N/A-1N/A
3/31/2015N/A-2N/A-1N/A
12/31/2014N/A-2N/A-1N/A
9/30/2014N/A-2N/A0N/A
6/30/2014N/A-2N/A0N/A
3/31/2014N/A-2N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SBFM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: SBFM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SBFM is expected to become profitable in the next 3 years.

Revenue vs Market: SBFM's revenue (109.9% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: SBFM's revenue (109.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SBFM's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:28
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sunshine Biopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation